Is Keros Therapeutics, Inc. KROS stock halal to invest in?

No, as of February 2026, Keros Therapeutics, Inc. stock (KROS) is currently categorized as NOT Shariah Compliant. The company's status is determined by a rigorous financial screening process, which uses the criteria set by the AAOIFI (Accounting and Auditing Organization for Islamic Financial Institutions) as the primary global standard for Islamic investing. Keros Therapeutics, Inc. has been assessed to have exceeded the permissible financial thresholds—specifically in areas like interest-bearing debt or non-permissible income (such as income from interest)—and, therefore, does not qualify as a halal investment under the current review. For investors seeking Shariah compliant global stocks, it is essential to check the latest compliance status, as these screenings are updated regularly (e.g., monthly) or upon the release of new financial reports. You can find the most current status for Keros Therapeutics, Inc. and alternative halal stock options within the Tabadulat app.

How often is Keros Therapeutics, Inc. KROS reviewed for Shariah compliance?

At Tabadulat, we receive Shariah compliance data on Keros Therapeutics, Inc. KROS monthly. We apply the rigorous AAOIFI screening methodology under the direct supervision of our dedicated Shariah Supervisory Board to ensure your investments are consistently compliant.

Does Keros Therapeutics, Inc. KROS pass the AAOIFI Non Permissible Income criteria?

Yes, as of February 2026, Keros Therapeutics, Inc. stock (KROS) passes the AAOIFI Non Permissible Income criterion. The company's income from non-permissible sources, such as interest, is below the acceptable threshold set by AAOIFI.

Does Keros Therapeutics, Inc. KROS pass the AAOIFI Interest Bearing Investments criteria?

No, as of February 2026, Keros Therapeutics, Inc. stock (KROS) does not pass the AAOIFI Interest Bearing Investments criterion. The company's interest-bearing investments have exceeded the permissible threshold set by AAOIFI, indicating the stock is currently not Shariah compliant for this screen.

Does STOCK pass the AAOIFI Interest Bearing Debt criteria?

Yes, as of February 2026, Keros Therapeutics, Inc. stock (KROS) passes the AAOIFI Interest Bearing Debt criterion. The company's interest-bearing debt is below the acceptable threshold set by AAOIFI.

English

العربية

Be the First to Know!

Join our waitlist for exclusive early access to Tabadulat’s Shariah-compliant trading platform. Get notified as soon as we go live and start investing with confidence.

Keros Therapeutics, Inc.

NASDAQ

Shariah-Compliant

Not Shariah

KROS

About

Keros Therapeutics, Inc.

KROS

Keros Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of groundbreaking treatments for hematological and musculoskeletal disorders. The company's primary aim is to address unmet medical needs by advancing innovative therapies that target the transforming growth factor-beta (TGF-beta) family of proteins. These proteins play a critical role in the regulation of cellular growth and development, making them pivotal in treating a variety of severe diseases. Keros Therapeutics is deeply involved in research and development, with a strong pipeline of drug candidates aimed at conditions such as anemia and other blood-related disorders, as well as muscle diseases that impact patient mobility. By targeting these specific biological pathways, Keros is contributing significantly to the biopharmaceutical industry’s efforts in developing more effective and personalized medicine. The company's operations are an important part of the healthcare sector, striving to deliver breakthroughs that can enhance the quality of life for patients worldwide.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

Website:

https://www.kerostx.com

KROS

Frequently asked questions

Related stocks

Mobile login screen for Tabadulat with fields to enter email, a Continue button, an option to create an account, and a language selector showing EN.

Step 1

Sign Up.

Begin by creating your Tabadulat account. Simply enter your details and complete the verification process. You’ll be up and running in no time.

Mobile screen showing add money interface with 100 AED amount and Manual Bank Transfer payment method selected, noting 1-2 business days processing.

Step 2

Deposit.

Add funds to your account using a secure payment method. You can deposit in multiple currencies to get started.

Step 3

Screen.

Screen Stocks for Free and explore a wide range of stocks that are ethically screened for Shariah compliance. Use our Halal Stock Screener to find the best opportunities.

Step 4

Trade.

Once you’ve chosen the right stocks, simply place your trades. Our platform offers real-time market data and seamless execution.

Mobile screen showing investment portfolio with $100,000 total value, $48,000 invested, and a $2,000 return (4.50%) with a line graph and options for 1W, 1M, 3M, YTD, 1Y, Max, plus Trade and Deposit buttons.

Step 5

Track.

Track your Portfolio and monitor your investments with our easy-to-use dashboard. View your portfolio performance, manage assets, and make adjustments as needed.

Step 6

Withdraw.

When you're ready, withdraw your funds quickly and securely to your bank account.

Keros Therapeutics, Inc.

About

Keros Therapeutics, Inc.

KROS

Frequently asked questions

Is Keros Therapeutics, Inc. KROS stock halal to invest in?

How often is Keros Therapeutics, Inc. KROS reviewed for Shariah compliance?

Does Keros Therapeutics, Inc. KROS pass the AAOIFI Non Permissible Income criteria?

Does Keros Therapeutics, Inc. KROS pass the AAOIFI Interest Bearing Investments criteria?

Does STOCK pass the AAOIFI Interest Bearing Debt criteria?

How do I buy Keros Therapeutics, Inc. KROS stock?

Sign Up.

Deposit.

Screen.

Trade.

Track.

Withdraw.